Shares of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions firm Lantheus Holdings (NASDAQ: LNTH) are surging premarket after the US Food and Drug Administration (FDA) approved PYLARIFY.
PYLARIFY is an imaging agent used to identify suspected metastasis or recurrence of prostate cancer.
According to Lantheus, PYLARIFY is the first and only commercially available approved PSMA PET imaging agent for prostate cancer.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Mary Anne Heino, President and CEO of Lantheus, described the FDA approval as a “significant milestone,” stating that PYLARIFY “represents a paradigm shift in the identification and management of patients with suspected metastasis or recurrent prostate cancer, providing more accurate and earlier detection of disease than conventional imaging.”
PYLARIFY was developed to target PSMA, a protein overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells. PYLARIFY binds to the target, enabling the reader of the PET scan to detect and locate the disease.
The approval of PYLARIFY is based on data from two studies (OSPREY and CONDOR) designed to establish the safety and diagnostic performance across prostate cancer disease.
Lantheus Holdings share price has rallied premarket, up 23.27% at $24.05.
Should You Invest in Lantheus Holdings Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
